Camilla Genovese

Camilla Genovese

Auto-generated profile, based on publicly available information

Camilla Genovese

Department of Infectious Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
MCMarta Colaneri
Marta Colaneri
EGEmanuele Maria Giusti
Emanuele Maria Giusti
CGCamilla Genovese
Camilla Genovese
LGLucia Galli
Lucia Galli
Andrea LombardiAndrea Lombardi
Andrea Lombardi
AGAndrea Gori
Andrea Gori
Mortality of candidemia in coronavirus disease 2019 (COVID-19) patients has not been deeply studied despite evidence suggesting an increased occurrence. We performed a systematic review and meta-analysis to summarize the available evidence about these patients’ mortality and length of stay. Data about the in-hospital, all-cause and 30-day mortality, and length of stay were pooled. Subgroup analyses were performed to assess sources of heterogeneity. Twenty-six articles out of the 1915 records retrieved during the search were included in this review. The pooled in-hospital mortality was 62.62% (95% CI, 54.77% to 69.86%), while the mortality in intensive care unit (ICU) was 66.77% (95% CI, 57.70% to 74.75%). The pooled median in-hospital length of stay was 30.41 (95% CI, 12.28 to 48.55) days, while the pooled median length of stay in the ICU was 28.28 (95% CI, 20.84 to 35.73) days. The subgroup analyses did not identify the sources of heterogeneity in any of the analyses. Our results showed high mortality in patients with candidemia and COVID-19, suggesting the need to consider screening measures to prevent this life-threatening condition.

21 April 2024 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
MCMarta Colaneri
Marta Colaneri
CGCamilla Genovese
Camilla Genovese
FFFederico Fassio
Federico Fassio
Marta CanutiMarta Canuti
Marta Canuti
AGAndrea Giacomelli
Andrea Giacomelli
AGAndrea Gori
Andrea Gori
Introduction Recent studies have highlighted the prognostic value of easily accessible inflammatory markers, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) for predicting severe outcomes in patients affected by Coronavirus disease 2019 (COVID-19). Our study validates NLR and PLR cut-off values from a prior cohort at IRCCS Policlinico San Matteo (OSM) of Pavia, Italy, across two new cohorts from different hospitals. This aims to enhance the generalizability of these prognostic indicators. Methods In this retrospective cohort study, conducted at Milan’s Ospedale Luigi Sacco (OLS) and IRCCS Ospedale Maggiore Policlinico (OMP) hospitals, we assess the predictive capacity of NLR and PLR for three main outcomes—non-invasive ventilation (NIV) or continuous positive airway pressure (CPAP) usage, invasive ventilation (IV), and death—in patients with COVID-19 at admission. For each outcome, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were computed separately for male and female cohorts. Distinct NLR and PLR cut-off values were used for men (7.00, 7.29, 7.00 for NLR; 239.22, 248.00, 250.39 for PLR) and women (6.36, 7.00, 6.28 for NLR; 233.00, 246.45, 241.54 for PLR), retrieved from the first cohort at OSM. Results A total of 3599 patients were included in our study, 1842 from OLS and 1757 from OMP. OLS and OMP sensitivity values for both NLR and PLR (NLR: 24–67%, PLR: 40–64%) were inferior to specificity values (NLR: 64–76%, PLR: 55–72%). Additionally, PPVs generally remained lower (< 63%), while NPVs consistently surpassed 68% for PLR and 72% for NLR. Finally, both PLR and NLR exhibited consistently higher NPVs for more severe outcomes (> 82%) compared to NPVs for CPAP/NIV. Conclusions Consistent findings across diverse patient populations validate the reliability and applicability of NLR and PLR cut-off values. High NPVs emphasize their role in identifying individuals less likely to experience severe outcomes. These markers not only aid in risk stratification but also guide resource allocation in emergencies or limited-resource situations.

6 June 2025 in American Journal of Infection Control
Verified
Journal Article
Closed access
FBFabio Borgonovo
Fabio Borgonovo
MCMarta Colaneri
Marta Colaneri
FFFederico Fassio
Federico Fassio
GSGiovanni Scaglione
Giovanni Scaglione
LGLucia Galli
Lucia Galli
AFAntonella Foschi
Antonella Foschi

10 August 2026 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
CGCamilla Genovese
Camilla Genovese
MCMarta Colaneri
Marta Colaneri
ESEnrico Sguazzini
Enrico Sguazzini
DMDonatella Maddalena
Donatella Maddalena
MAMohd-Hafiz Abdul-Aziz
Mohd-Hafiz Abdul-Aziz
MUMarat Ulldemolins
Marat Ulldemolins
Ceftaroline and ceftobiprole are fifth-generation cephalosporins with activity against methicillin-resistant Staphylococcus aureus. Like other β-lactam antimicrobials, their efficacy correlates with the percentage of the dosing interval during which unbound drug concentrations exceed the minimum inhibitory concentration (MIC) of the pathogen (% fT>MIC). However, achieving optimal exposures may be challenging in patients with altered pharmacokinetics or deep-seated infections. A systematic review was performed using MEDLINE (Pubmed), Embase, Web of Science and Scopus libraries. Peer-reviewed studies reporting the pharmacokinetics of ceftaroline and ceftobiprole and/or their pharmacokinetics/pharmacodynamics in S. aureus infections were included. Screening, data extraction, and quality assessment were performed independently by two reviewers. Thirty-one studies for ceftaroline and 22 studies for ceftobiprole met the inclusion criteria. Literature appraisal revealed substantial pharmacokinetic variability in special populations, particularly critically ill patients, with increased volumes of distribution and variable clearance. In patients without severe infections, standard dosing generally achieved high probabilities of attaining pre-clinical pharmacokinetic/pharmacodynamic targets for bacteriostasis, 1-log₁₀ and 2-log₁₀ kill (20%, 26%, and 37% fT>MIC for ceftaroline, 8.8%, 13.5%, and 23% for ceftobiprole) up to the clinical breakpoints. By contrast, in patients with altered pharmacokinetics or deep-seated infections, intensified dosing and prolonged infusions were often required to achieve plasma and tissue pharmacokinetic/pharmacodynamic targets, particularly for stringent endpoints such as 100% fT>MIC. Ceftaroline and ceftobiprole pharmacokinetics are highly variable in hospitalized patients, potentially compromising attainment of stringent pharmacokinetic/pharmacodynamic targets for S. aureus infections. Intensified doses and prolonged infusions may therefore be necessary to ensure adequate drug exposure.

1 October 2024 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
Marta CanutiMarta Canuti
Marta Canuti
FFFederico Fassio
Federico Fassio
CGCamilla Genovese
Camilla Genovese
AGAndrea Giacomelli
Andrea Giacomelli
ARAnna Lisa Ridolfo
Anna Lisa Ridolfo
MCMarta Colaneri
Marta Colaneri
A Multi-Cohort Validation Study" [1]. We are grateful for the acknowledgment and recognition of our work and for the valuable reflections, which we believe will enhance the ongoing dialogue in this critical area of research. We would like to take this opportunity to further elaborate on the significance of our research. We acknowledge that some elements of patients' histories mentioned by Zhang and Wang [2], such as anti-inflammatory or bone marrow toxicity medication use, vaccine use, smoking status, occupational factors, lifestyle, and non-pharmacological psychological factors, might have an influence on both patients' outcome and the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) measurements. However, during emergency